Pentravan®: new route of administration for innovative treatments

Tue, 11/10/2015
Pentravan®: new route of administration for innovative treatments

Pentravan® has demonstrated to be an effective vehicle for the administration of hormones via the vaginal mucosa[1-6]. This route of administration provides high tissue levels of hormones and other active pharmaceutical ingredients (APIs) in the pelvic region, with relatively low systemic blood levels that can cause androgenic side effects[7]. This makes vaginal administration with Pentravan® a very promising route for treating women with a variety of hormonal related conditions.

In a recently published open clinical trial 47 patients with endometriosis and pain were treated with vaginal application of gestrinone in Pentravan®, together with oral pinus pinaster extract and resveratrol (natural polyphenols with antioxidant and anti inflammatory properties) daily.

These patients scored their pain at 9 out of 10 before treatment. After three months all patients were pain-free, bleeding stopped and uterine and ovarian cyst volume decreased. There were no statistically significant changes in total cholesterol, baseline FSH or LH. HDL-cholesterol, triglycerides, total testosterone and estradiol levels decreased significantly. These preliminary results show that vaginal application gestrinone in Pentravan® with oral resveratrol and pinus pinaster extract is an effective treatment for endometriosis-related pain [8].

More information about Pentravan® can be found here, and by contacting your local Fagron office.


[1] Lehman PA, Raney SG. In vitro percutaneous absorption of ketoprofen and testosterone: comparison of pluronic lecithin organogel vs. pentravan cream. Int J Pharm Compd. 2012;16(3):248-52.
[2] H. Maia Jr.1,2, C. Haddad2, R. Maia2 et al. Pulsatile administration of testosterone by the vaginal route using Pentravan®. Monduzzi Editoriale. 2013;181-184.
[3] Polonini HC, de Bastos CA, de Oliveira MA et al. In vitro drug release and ex vivo percutaneous absorption of resveratrol cream using HPLC with zirconized silica stationary phase. J Chromatogr B Analyt Technol Biomed Life Sci. 2014;947-948:23-31.
[4] Hudson CP, Pedro PSm Marcone ALO et al. Transdermal formulations containing human sexual steroids: development and validation of methods and in vitro drug release. Quím. Nova. 2014;37(4):720-728.
[5] Polonini HC, Brandão MAF, Ferreira AO et al. Evaluation of Percutaneous Absorption Performance for Human Female Sexual Steroids into Pentravan Cream. IJPC 2014; 18(4):332-340.
[6] de Almeida PA, Alves MC, Polonini HC et al. Studies with emulsion containing trans-resveratrol: in vitro release profile and ex vivo human skin permeation. Curr Drug Deliv. 2015;12(2):157-65.
[7] Dominique De Ziegler, Carlo Bulletti, Béatrice de Monstier et al. The First Uterine Pass Effect. The Uterus: Endometrium and Myometrium, Annals of the New York Academy of Sciences.1997; 828: 291-299.
[8] Maia H Jr, Haddad C, dos Santos Junior WSD, et al.  Clinical Experience with Vaginal Gestrinone in Pentravan® in the Treatment of Endometriosis Pain. Austin J Reprod Med Infertil. 2015; 2(4): 1021.